Drug Trial Radar · NCT03701334
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
5,101
Actual
Start
Dec 7, 2018
Primary completion
May 29, 2030
Study completion May 29, 2030
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- Collaborators
- Translational Research in Oncology
- First posted
- Oct 10, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase III, multicenter, randomized, open-label trial to evaluate the efficacy and safety of ribociclib with Endocrine Therapy (ET) as an adjuvant treatment in women and men with Hormone Receptor positive (HR+), Human Epidermal Growth Factor Receptor 2 negative (HER2-) Early Breast Cancer (EBC).
Conditions
- Early Breast Cancer
Interventions
RibociclibDrug
Ribociclib orally taken at 400 mg on days 1 to 21 of a 28-day cycle
Endocrine Therapy (ET)Other
Endocrine Therapy (ET) will be administered according to the local clinical guidelines and current local prescribing information
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive Disease-Free Survival (iDFS)Time frame: Up to approximately 139 months
Locations
387 sites in 20 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham-Kirklin Clinic
Birmingham, Alabama
Cancer Treatment Centers of America
Goodyear, Arizona
St Bernards Medical Center
Jonesboro, Arkansas
Comprehensive Blood and Cancer
Bakersfield, California
UCLA Beverly Hills
Beverly Hills, California
UCLA Burbank
Burbank, California
Encino Research Center
Encino, California
St. Jude Heritage Medical Group
Fullerton, California
UCLA Hematology Oncology
Laguna Hills, California
Southern CA Oncology Rsrch Alliance
Los Angeles, California
Stanford University Medical Center
Palo Alto, California
UCLA Pasadena HC Hemato Onco
Pasadena, California
UCLA Porter Ranch Hemato and Onco
Porter Ranch, California
Cancer Care Associates Medical Grp
Redondo Beach, California
Sharp Memorial Hospital
San Diego, California
UCSF
San Francisco, California
Central Coast Medical Oncology Corporation
Santa Maria, California
UCLA Santa Monica Hematology Oncology
Santa Monica, California
Lundquist Inst BioMed at Harbor
Torrance, California
UCLA Valencia
Valencia, California
Valley Breast Care
Van Nuys, California
UCLA Cancer Center Westlake Village
Westlake Village, California
University Of Colorado Hospital
Aurora, Colorado
Rocky Mountain Cancer Centers
Denver, Colorado
Hospital of Central Connecticut
New Britain, Connecticut
Yale University School Of Medicine
New Haven, Connecticut
Norwalk Hospital
Norwalk, Connecticut
Eastern Connecticut Hematology and Oncology Associates
Norwich, Connecticut
Holy Cross Hospital-Ft. Lauderdale
Fort Lauderdale, Florida
Florida Cancer Specialists
Fort Myers, Florida
Memorial Cancer Institute
Hollywood, Florida
Baptist MD Anderson Cancer Center
Jacksonville, Florida
University of Miami
Miami, Florida
Orlando Health Clinical Trials
Orlando, Florida
Florida Cancer Specialists-North
St. Petersburg, Florida
Florida Cancer Specialists Pan
Tallahassee, Florida
Florida Cancer Specialists
West Palm Beach, Florida
Winship Cancer Institute of Emory University
Atlanta, Georgia
Southeastern Regional Medical Center
Newnan, Georgia
Cancer Treatment Centers of America
Zion, Illinois
Showing 40 of 387 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.